The Hidden Cost of Late Execution Strategy: Why Most Sponsors Are Solving the Wrong Problem at the Wrong Time

By the time a contract research organization is in place, most of the decisions that will determine whether a study succeeds or struggles have already been made. The protocol assumptions are set, the enrollment projections are locked, and the timeline has been communicated to investors.

What hasn’t been tested is whether any of it reflects operational reality.

In early-stage development, where funding timelines create pressure to advance programs quickly, execution strategy is often a blind spot in development planning. Critical operational assumptions go untested until execution forces them into view.

When these gaps surface during execution, the initial response is often to look at vendor performance, site behavior, or clinical operations delivery. The real source is earlier and less visible: a strategy timing problem that is one of the most expensive and preventable sources of execution instability in clinical development.

This article examines why execution instability often originates in strategy timing rather than study conduct and how sponsors can correct this by integrating execution oversight expertise earlier in development decisions. The sequencing is familiar: Science defines the program, regulatory maps the pathway, and clinical operations is engaged to operationalize what has already been decided.

By the time execution expertise enters the conversation, protocol assumptions are largely fixed, enrollment projections have shaped investor expectations, and vendor timelines are being negotiated against budgets that were never pressure-tested against operational reality. This sequencing feels logical—strategy precedes execution, and planning precedes delivery. But it misidentifies what execution strategy actually is.

Execution strategy is not a downstream activity. It is the continuous process of testing whether scientific intent can be reliably translated into operational reality across sites, vendors, systems, and patients before commitments make that translation expensive to correct.

When the execution strategy is deferred, assumptions don’t disappear. They harden into contracts, timelines, and financial projections communicated to boards and investors. By the time they are tested against operational reality, they are no longer assumptions. They are embedded impediments.

The consequences of a deferred execution strategy rarely announce themselves as strategy failures. They surface during start-up and execution, labeled as vendor performance issues, site activation delays, protocol complexity problems, or clinical operations performance failures.

The diagnosis stops at the symptom, but the misdiagnosis matters. When the root cause is attributed to execution, corrective action targets the wrong stage and the wrong team.

The planning decisions that created the condition go unexamined, and the same assumptions travel forward into the next program. Enrollment projections that looked reasonable at protocol finalization prove unrealistic once sites are activated.

Patient prevalence, site capability, and competitive landscape were never tested against execution reality. They were inherited from historical benchmarks or optimistic modeling and hardened into investor commitments before anyone with site-level experience examined them.

Protocol amendments emerge during start-up to address feasibility gaps that were visible earlier but never surfaced, including the following:

• Visit schedules that burden patients beyond what sites can manage
• Inclusion criteria that eliminate the available population
• Procedures misaligned with standard of care

Each amendment carries timeline and budget consequences that compound across vendors, sites, and functions. Change orders accumulate, and vendors are contracted against a scope that was defined before operational assumptions were fully owned by the sponsor.

Those assumptions will prove incomplete, and when they do, the cost of resolution lands in change orders that were entirely predictable and almost entirely avoidable. In one program, a study delay was traced to an issue with the investigational product (IP) presentation that impacted study supply.

The implications were not fully understood during early planning and became visible only as logistics and execution start-up began. Addressing the issue required changes to the study scope and operational approach, resulting in delays and additional costs.

This was not an execution-stage surprise. It reflected a gap in early strategy, where cross-functional integration across chemistry, manufacturing, and controls (CMC); quality; and clinical execution had not been fully established to confirm trial readiness.

Execution did not create the problem; it revealed it. An early execution strategy is not a planning checklist, a project management activity, or a risk register exercise. It is the sustained engagement of qualified operational expertise at the point where development assumptions are first formed—before they are tested by reality and before correction becomes expensive. In practice, this means the execution strategy begins at the business decision.

When a sponsor commits to advancing an asset, the assumptions that will shape every downstream commitment begin forming immediately. Feasibility, IP supply, resourcing, vendor scope, and timeline are not operational details to be resolved later. They are strategic variables that determine whether execution is possible as designed. An early execution strategy asks different questions compared with a late one:

• Early asks: Can this protocol be implemented as written, in the sites we are considering, with the patients available, within the timeline we have communicated?
• Early asks: Is this scope defined well enough to be priced accurately, and have we pressure-tested the assumptions behind it before we commit to it contractually?
• Late asks: How do we implement this protocol?
• Late asks: Which vendor can deliver this scope?

The difference is not procedural; it is positional. Early execution strategy requires that operational expertise be present where assumptions are formed: in portfolio decisions, protocol development, IP planning, feasibility modeling, and vendor strategy, and not introduced after those decisions have already shaped commitments.

This is not about slowing development. Organizations that integrate execution strategy early do not move more slowly. They move with fewer corrections. Timelines are more credible because they reflect operational reality. Budgets are more defensible because they were built against tested assumptions. The goal is not to predict everything but rather to own the assumptions before they own the program.

International Council for Harmonisation Good Clinical Practice (ICH GCP) E6(R3) does not ask sponsors to build more process. It asks sponsors to maintain proportionate, risk-based oversight through informed decisions made continuously across the study lifecycle. That expectation begins when development assumptions are first formed.

Quality by design, the organizing principle behind E6(R3) is more than a quality department function. It is how every function involved in clinical development is expected to operate. Preclinical, regulatory, CMC, clinical operations oversight, and data management decisions should be made with intention, rigor, and execution feasibility in mind from the outset with active facilitation, not handed off downstream or retrofitted after the fact.

When an execution strategy is deferred, sponsors not only take an operational risk but also distance themselves from how the program was designed and what the regulation actually requires. That gap becomes visible during inspections, not before them.

Sponsor oversight is not demonstrated by documents approved or meetings attended. It is demonstrated by whether the sponsor maintained informed control of the study from the earliest strategic decisions forward. That standard cannot be demonstrated retroactively.

Preventing execution instability requires more than recognizing its origins. It requires deliberate evaluation of the operational decisions made during the early development strategy.

Practically, this means asking different questions before commitments are made:

• Which elements of the trial design carry the highest operational sensitivity?
• What assumptions about supply, sites, patients, vendors, and timelines must hold for the design to work as intended?
• Where cross-functional dependencies exist, which functional domain owns them, and what structures will support reliable delivery?

These are design questions. Most valuable before the protocol is finalized, before vendors are contracted, and before timelines are communicated externally. Quality by design begins in strategy. The planning, design, and execution decisions made in early strategy are the most effective safeguard a sponsor can build.

They cannot be retrofitted after commitments harden. They must be designed in from the start. None of this requires large teams or enterprise-scale infrastructure. It requires that the right expertise be present at the right decision points, present early enough to shape assumptions rather than inherit them.

The question most sponsors ask after a difficult study is: What went wrong during execution? It is the wrong question.

The more useful questions are the following:

• What was decided during the strategy that made this outcome predictable?
• Where were the assumptions that no one owned?
• Which commitments hardened before execution expertise was in the room?
• What would have been different if operational reality had entered the conversation 6 months earlier?

Clinical execution is not the phase where things go wrong; it is the phase where earlier decisions become visible. The stability or instability that appeared during a trial was largely determined before the first site was activated.

The sponsors who recognize this earliest spend less time recovering from assumptions they never tested. They spend more time delivering against plans built to withstand contact with reality.

The window to design for that outcome is open now. It closes earlier than most organizations expect.

About the Author

Elizabeth Walsh, PMP, ACRP-CP, is a clinical development executive specializing in execution strategy and delivery across complex development programs. With more than 25 years of experience spanning sponsor organizations, contract research organizations, and research environments, she has led global phase 1 to 4 programs from early development through regulatory submission and commercialization. Her work focuses on integrating clinical execution into development strategy, ensuring operational assumptions are tested early and sponsor oversight remains active across outsourced models. She has built and led clinical operations organizations; supported investigational new drug applications, new drug applications, abbreviated new drug applications, and biologics license applications; and guided programs across oncology, rare disease, neurology, immunology, and infectious disease. She is the founder of Walsh Clinical Advisory, where she advises biotech sponsors on clinical execution and oversight.